On Mar. 27, 2020, Luminex announced the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for its NxTAG CoV Extended Panel. The intended use of this multiplex test is the detection of the SARS-CoV-2 virus.

High complexity molecular laboratories can now use the NxTAG test on Luminex’s easy-to-use, compact MAGPIX System to rapidly detect the virus that causes COVID-19 disease for up to 96 patients in approximately 4 hours.